Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of MGC018 (Anti-B7-H3 Antibody Drug Conjugate) Alone and in Combination With MGA012 (Anti-PD-1 Antibody) in Patients With Advanced Solid Tumors

Trial Profile

A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of MGC018 (Anti-B7-H3 Antibody Drug Conjugate) Alone and in Combination With MGA012 (Anti-PD-1 Antibody) in Patients With Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 25 Jan 2019

At a glance

  • Drugs INCMGA 0012 (Primary) ; MGC-018 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors MacroGenics
  • Most Recent Events

    • 25 Jan 2019 According to a MacroGenics media release, enrollment of the first dose escalation cohort has been completed.
    • 25 Jan 2019 Status changed from not yet recruiting to recruiting, according to a MacroGenics media release.
    • 09 Nov 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top